Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)WXIBF 100 Debt-to-EBITDA is 0.39 as of Dec. 2025, which is 56% below its 10-year median of 0.89. GuruFocus rates WXIBF with a GF Score™ of 100/100 and a GF Value™ of $5.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 291 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 65.98% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Debt-to-EBITDA or its related term are showing as below:
WXIBF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.35 Med: 0.89 Max: 3.85
Current: 0.42
During the past 12 years, the highest Debt-to-EBITDA Ratio of WuXi Biologics (Cayman) was 3.85. The lowest was 0.35. And the median was 0.89.
WXIBF's Debt-to-EBITDA is ranked better than 65.98% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs WXIBF: 0.42
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
WuXi Biologics (Cayman) Debt-to-EBITDA Related Terms
WuXi Biologics (Cayman) Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
WuXi Biologics (Cayman) (WXIBF) has a Debt-to-EBITDA of 0.39 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on WuXi Biologics (Cayman). This is 56% below median its historical median of 0.89. Over the past decade, WuXi Biologics (Cayman)'s Debt-to-EBITDA has ranged from 0.35 to 3.85. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #99 out of 291 companies in the Biotechnology industry, placing it in the top 34%.
Is WuXi Biologics (Cayman)'s Debt-to-EBITDA too high?
WuXi Biologics (Cayman)'s current Debt-to-EBITDA of 0.39 is 56% below median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 3.85. The Biotechnology industry median Debt-to-EBITDA is 1.14. WuXi Biologics (Cayman)'s value of 0.39 is 65.8% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #99 out of 291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #99 out of 291 companies for Debt-to-EBITDA. This puts WuXi Biologics (Cayman) in the upper half of its industry. The industry median Debt-to-EBITDA is 1.14. WuXi Biologics (Cayman)'s value of 0.39 is 65.8% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Debt-to-EBITDA has ranged from 0.35 to 3.85 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 1.14, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Debt-to-EBITDA of 0.39 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on WuXi Biologics (Cayman). For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Debt-to-EBITDA is 0.39, which is 56% below median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.19, compared to a current price of $4.60 — trading 11.4% below its estimated fair value. The current Debt-to-EBITDA is 0.39, which is 56% below median its 10-year median of 0.89 and 65.8% below the Biotechnology industry median of 1.14. WuXi Biologics (Cayman)'s overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Debt-to-EBITDA is 0.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.60 is trading 11.4% below its estimated GF Value™ of $5.19.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
Debt-to-EBITDA: 0.39 (56% below median its 10-year median of 0.89)
GF Value™: $5.19 vs. price of $4.60 (11.4% below fair value)
Industry Position: 65.8% below the Biotechnology median (#99 of 291)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
100GF Score
Get the complete analysis for WXIBF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
